Immunocore Holdings plc last reported quarterly results on Aug 6, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $115.9 million (+18.3% year over year) and diluted EPS of -$0.02. It usually reports 9–37 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 5, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 6, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 9–37 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
116
+18.3%
|
-1
+92.2%
|
-0.02
+90.0%
|
|
May 6, 2026
36 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
107
+13.6%
|
13
+158.2%
|
0.25
+150.0%
|
|
Jan 9, 2026
9 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
104
|
-30
-26.5%
|
-0.59
-25.1%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
104
+29.2%
|
-0
-102.0%
|
0.00
-100.0%
|
|
Aug 7, 2025
38 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
98
+29.9%
|
-10
+11.3%
|
-0.20
+13.0%
|
|
May 7, 2025
37 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
94
+33.2%
|
5
+120.6%
|
0.10
+120.4%
|
|
Jan 10, 2025
10 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
—
|
-24
|
-0.47
|
|
Nov 6, 2024
37 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
80
|
9
|
0.17
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IMCR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- Oxfordshire, United Kingdom
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1671927
- Former names
- Immunocore Ltd (until Feb 1, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.